Effect of topical diflumidone on ultraviolet-light-induced erythema.
The relative topical efficacy of indomethacin and diflumidone, a novel non-steroidal antiinflammatory drug, for the suppression of ultraviolet-light (290-320 nm region; UVB)-induced erythema has been compared in a randomized, double-blind, placebo-controlled study in man. During the early phases of erythema development (3-6 h) following the administration of 3 minimal erythema doses (MED) of UVB, a single topical application of diflumidone and of indomethacin were found to be equal in their ability to inhibit the development of erythema compared to untreated or placebo-treated sites. At 24 h after application, the indomethacin-treated sites had significantly less erythema than did the diflumidone-treated sites. Pigmentation of test sites at 5 and 14 days following irradiation was indistinguishable at the diflumidone, placebo, or untreated sites, but relatively less pigment developed at the indomethacin-treated sites.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use*; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D001577:Benzophenones; D013449:Sulfonamides; C000962:diflumidone; D007213:Indomethacin